Javascript must be enabled to continue!
Effect of Docetaxel on Matrix Metalloproteinase 1 Expression in Freund’s Adjuvant Induced Arthritis
View through CrossRef
Rheumatoid arthritis is an autoimmune disorder that affects the synovial joints. It lead to inflammatory changes occur in synovial tissue, cartilage, bone, and, less frequently, extra-articular structures. Docetaxel, is an anti-neoplastic drug. Methotrexate is a treatment for early-stage rheumatoid arthritis but have 30% failure in treatment within the first year due to resistance or side effects. Matrix metalloproteinase 1 is the proteinase primarily in charge of the irreversible degradation of cartilage, bone, and tendons in the joints, which are induced by cytokines. This study aims to evaluate the effects of docetaxel and methotrexate on Matrix metalloproteinase 1 in the structure of the induced arthritis joints. Methods: To induce the disease, complete Freund's adjuvant is injected subcutaneously into rats. From the 40 male Wister rats, five groups of eight were formed. The control group is composed of non-diseased rats. The second group is induced by complete Freund's adjuvant and 0.5 ml of normal saline was administered intraperitoneally to both the control and induction groups. After being induced by complete Freund's adjuvant, the third group is administered 1 mg/kg/ on alternate day of Docetaxel based on a preliminary experiment. The fourth group is induced and given 1 mg/kg/week of Methotrexate intraperitoneally. The fifth group receives a half dose of Methotrexate and Docetaxel simultaneously. Serum level of Anti Cyclical citrullinated Peptide Antibody, tissue homogenate level of tumor necrosis factor-alpha, knee joint circumference and Immunohistochemical of Matrix metalloproteinase 1 measurements were applied. Results: Significant decreased in the Serum level of Anti-Cyclic citrullinated Peptide Antibody, tissue homogenate level of tumor necrosis factor-alpha & Knee joint circumference in the Docetaxel group. significant lowering in the expression of Matrix metalloproteinase 1 immunoreactivities in Docetaxel and Methotrexate groups with almost absent spots of positive reaction with the matrix of synovial tissue, hyaline cartilage & articular surface. Conclusion: This study showed that Docetaxel may have anti-arthritic effect through their significant lowering expression of Matrix metalloproteinase 1 immunoreactivities.
College of Pharmacy University of Baghdad
Title: Effect of Docetaxel on Matrix Metalloproteinase 1 Expression in Freund’s Adjuvant Induced Arthritis
Description:
Rheumatoid arthritis is an autoimmune disorder that affects the synovial joints.
It lead to inflammatory changes occur in synovial tissue, cartilage, bone, and, less frequently, extra-articular structures.
Docetaxel, is an anti-neoplastic drug.
Methotrexate is a treatment for early-stage rheumatoid arthritis but have 30% failure in treatment within the first year due to resistance or side effects.
Matrix metalloproteinase 1 is the proteinase primarily in charge of the irreversible degradation of cartilage, bone, and tendons in the joints, which are induced by cytokines.
This study aims to evaluate the effects of docetaxel and methotrexate on Matrix metalloproteinase 1 in the structure of the induced arthritis joints.
Methods: To induce the disease, complete Freund's adjuvant is injected subcutaneously into rats.
From the 40 male Wister rats, five groups of eight were formed.
The control group is composed of non-diseased rats.
The second group is induced by complete Freund's adjuvant and 0.
5 ml of normal saline was administered intraperitoneally to both the control and induction groups.
After being induced by complete Freund's adjuvant, the third group is administered 1 mg/kg/ on alternate day of Docetaxel based on a preliminary experiment.
The fourth group is induced and given 1 mg/kg/week of Methotrexate intraperitoneally.
The fifth group receives a half dose of Methotrexate and Docetaxel simultaneously.
Serum level of Anti Cyclical citrullinated Peptide Antibody, tissue homogenate level of tumor necrosis factor-alpha, knee joint circumference and Immunohistochemical of Matrix metalloproteinase 1 measurements were applied.
Results: Significant decreased in the Serum level of Anti-Cyclic citrullinated Peptide Antibody, tissue homogenate level of tumor necrosis factor-alpha & Knee joint circumference in the Docetaxel group.
significant lowering in the expression of Matrix metalloproteinase 1 immunoreactivities in Docetaxel and Methotrexate groups with almost absent spots of positive reaction with the matrix of synovial tissue, hyaline cartilage & articular surface.
Conclusion: This study showed that Docetaxel may have anti-arthritic effect through their significant lowering expression of Matrix metalloproteinase 1 immunoreactivities.
.
Related Results
Abstract 7173: Animal pharmacokinetics of an anti-Her2+ immunoliposome of docetaxel
Abstract 7173: Animal pharmacokinetics of an anti-Her2+ immunoliposome of docetaxel
Abstract
Despite the success of docetaxel in combination with trastuzumab in HER2+ breast cancer, docetaxel still has serious limitations, including poor water solub...
Histopathological evaluation of docetaxel effects in treatment of rheumatoid arthritis induced in rat model
Histopathological evaluation of docetaxel effects in treatment of rheumatoid arthritis induced in rat model
Rheumatoid arthritis is an immune-mediated condition that affects synovial joints. Synovial tissue, cartilage, bone, and less frequently extra-articular structures which in turn ex...
Docetaxel in older patients for metastatic prostate cancer.
Docetaxel in older patients for metastatic prostate cancer.
187 Background: Docetaxel use has led to a significant prolongation in overall survival in metastatic prostate cancer (MPC). There is however limited information on treatment tole...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
298 Background: Docetaxel use has led to a significant prolongation in overall survival (OS) in metastatic prostate cancer after castrate resistance, with a more substantial OS ga...
THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
CYTOKINES IN SLE: LESSONS FROM EXPERIMENTAL MODELS AND MAN, Michael J Elliott*., Peter Charles, Ravinder N MainiTHE FAS GENE IN HUMAN LUPUS: THE EXPRESSION OF VARIANT TRANSCRIPTS.,...
Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer
Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer
AbstractDocetaxel is the widely-used first-line therapy to treat lung cancer around the world. However, tumor progression and severe side effect occurred in some patients with doce...
Use of Receiver Operating Characteristic (ROC) Analysis To Determine the Most Optimal Prognostic Threshold for Adjuvant! in Lymph Node Negative Breast Cancer Patients < 55 Years.
Use of Receiver Operating Characteristic (ROC) Analysis To Determine the Most Optimal Prognostic Threshold for Adjuvant! in Lymph Node Negative Breast Cancer Patients < 55 Years.
Abstract
Background: Adjuvant!1 is a web based tool to predict the 10-year relapse free survival (RFS), breast cancer specific survival (BCSS) and overall survival (...

